TNFSF13B and diffuse large B-cell lymphoma: In particular, compared with wild-type sBCMA-Fc, sTACI-Fc, and αBAFF Ab, sBCMA-Fc V3 treatment resulted in superior antitumor efficacy in a DLBCL model, likely driven by its strong binding toward BAFF.